Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury

Devika S. Manickam, Anna M. Brynskikh, Jennifer L. Kopanic, Paul L Sorgen, Natalia L. Klyachko, Elena V. Batrakova, Tatiana K Bronich, Alexander V. Kabanov

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Development of well-defined nanomedicines is critical for their successful clinical translation. A simple synthesis and purification procedure is established for chemically cross-linked polyion complexes of Cu/Zn superoxide dismutase (SOD1) or catalase with a cationic block copolymer, methoxy-poly(ethylene glycol)-block-poly(L-lysine hydrochloride) (PEG-pLL 50). Such complexes, termed cross-linked nanozymes (cl-nanozymes) retain catalytic activity and have narrow size distribution. Moreover, their cytotoxicity is decreased compared to non-cross-linked complexes due to suppression of release of the free block copolymer. SOD1 cl-nanozymes exhibit prolonged ability to scavenge experimentally induced reactive oxygen species (ROS) in cultured brain microvessel endothelial cells and central neurons. In vivo they decrease ischemia/reperfusion-induced tissue injury and improve sensorimotor functions in a rat middle cerebral artery occlusion (MCAO) model after a single intravenous (i.v.) injection. Altogether, well-defined cl-nanozymes are promising modalities for attenuation of oxidative stress after brain injury.

Original languageEnglish (US)
Pages (from-to)636-645
Number of pages10
JournalJournal of Controlled Release
Volume162
Issue number3
DOIs
StatePublished - Sep 28 2012

Fingerprint

Brain Injuries
Lysine
Antioxidants
Nanomedicine
Ethylene Glycol
Middle Cerebral Artery Infarction
Microvessels
Intravenous Injections
Catalase
Reperfusion
Reactive Oxygen Species
Oxidative Stress
Ischemia
Endothelial Cells
Neurons
Wounds and Injuries
Brain
Therapeutics
Superoxide Dismutase-1

Keywords

  • Antioxidant enzymes
  • Block ionomer complexes
  • Blood-brain barrier
  • Cross-linked nanozymes
  • Stroke therapy

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Manickam, D. S., Brynskikh, A. M., Kopanic, J. L., Sorgen, P. L., Klyachko, N. L., Batrakova, E. V., ... Kabanov, A. V. (2012). Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury. Journal of Controlled Release, 162(3), 636-645. https://doi.org/10.1016/j.jconrel.2012.07.044

Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury. / Manickam, Devika S.; Brynskikh, Anna M.; Kopanic, Jennifer L.; Sorgen, Paul L; Klyachko, Natalia L.; Batrakova, Elena V.; Bronich, Tatiana K; Kabanov, Alexander V.

In: Journal of Controlled Release, Vol. 162, No. 3, 28.09.2012, p. 636-645.

Research output: Contribution to journalArticle

Manickam, DS, Brynskikh, AM, Kopanic, JL, Sorgen, PL, Klyachko, NL, Batrakova, EV, Bronich, TK & Kabanov, AV 2012, 'Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury', Journal of Controlled Release, vol. 162, no. 3, pp. 636-645. https://doi.org/10.1016/j.jconrel.2012.07.044
Manickam, Devika S. ; Brynskikh, Anna M. ; Kopanic, Jennifer L. ; Sorgen, Paul L ; Klyachko, Natalia L. ; Batrakova, Elena V. ; Bronich, Tatiana K ; Kabanov, Alexander V. / Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury. In: Journal of Controlled Release. 2012 ; Vol. 162, No. 3. pp. 636-645.
@article{aebbec760e6e4be399f2e14c99acb857,
title = "Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury",
abstract = "Development of well-defined nanomedicines is critical for their successful clinical translation. A simple synthesis and purification procedure is established for chemically cross-linked polyion complexes of Cu/Zn superoxide dismutase (SOD1) or catalase with a cationic block copolymer, methoxy-poly(ethylene glycol)-block-poly(L-lysine hydrochloride) (PEG-pLL 50). Such complexes, termed cross-linked nanozymes (cl-nanozymes) retain catalytic activity and have narrow size distribution. Moreover, their cytotoxicity is decreased compared to non-cross-linked complexes due to suppression of release of the free block copolymer. SOD1 cl-nanozymes exhibit prolonged ability to scavenge experimentally induced reactive oxygen species (ROS) in cultured brain microvessel endothelial cells and central neurons. In vivo they decrease ischemia/reperfusion-induced tissue injury and improve sensorimotor functions in a rat middle cerebral artery occlusion (MCAO) model after a single intravenous (i.v.) injection. Altogether, well-defined cl-nanozymes are promising modalities for attenuation of oxidative stress after brain injury.",
keywords = "Antioxidant enzymes, Block ionomer complexes, Blood-brain barrier, Cross-linked nanozymes, Stroke therapy",
author = "Manickam, {Devika S.} and Brynskikh, {Anna M.} and Kopanic, {Jennifer L.} and Sorgen, {Paul L} and Klyachko, {Natalia L.} and Batrakova, {Elena V.} and Bronich, {Tatiana K} and Kabanov, {Alexander V.}",
year = "2012",
month = "9",
day = "28",
doi = "10.1016/j.jconrel.2012.07.044",
language = "English (US)",
volume = "162",
pages = "636--645",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury

AU - Manickam, Devika S.

AU - Brynskikh, Anna M.

AU - Kopanic, Jennifer L.

AU - Sorgen, Paul L

AU - Klyachko, Natalia L.

AU - Batrakova, Elena V.

AU - Bronich, Tatiana K

AU - Kabanov, Alexander V.

PY - 2012/9/28

Y1 - 2012/9/28

N2 - Development of well-defined nanomedicines is critical for their successful clinical translation. A simple synthesis and purification procedure is established for chemically cross-linked polyion complexes of Cu/Zn superoxide dismutase (SOD1) or catalase with a cationic block copolymer, methoxy-poly(ethylene glycol)-block-poly(L-lysine hydrochloride) (PEG-pLL 50). Such complexes, termed cross-linked nanozymes (cl-nanozymes) retain catalytic activity and have narrow size distribution. Moreover, their cytotoxicity is decreased compared to non-cross-linked complexes due to suppression of release of the free block copolymer. SOD1 cl-nanozymes exhibit prolonged ability to scavenge experimentally induced reactive oxygen species (ROS) in cultured brain microvessel endothelial cells and central neurons. In vivo they decrease ischemia/reperfusion-induced tissue injury and improve sensorimotor functions in a rat middle cerebral artery occlusion (MCAO) model after a single intravenous (i.v.) injection. Altogether, well-defined cl-nanozymes are promising modalities for attenuation of oxidative stress after brain injury.

AB - Development of well-defined nanomedicines is critical for their successful clinical translation. A simple synthesis and purification procedure is established for chemically cross-linked polyion complexes of Cu/Zn superoxide dismutase (SOD1) or catalase with a cationic block copolymer, methoxy-poly(ethylene glycol)-block-poly(L-lysine hydrochloride) (PEG-pLL 50). Such complexes, termed cross-linked nanozymes (cl-nanozymes) retain catalytic activity and have narrow size distribution. Moreover, their cytotoxicity is decreased compared to non-cross-linked complexes due to suppression of release of the free block copolymer. SOD1 cl-nanozymes exhibit prolonged ability to scavenge experimentally induced reactive oxygen species (ROS) in cultured brain microvessel endothelial cells and central neurons. In vivo they decrease ischemia/reperfusion-induced tissue injury and improve sensorimotor functions in a rat middle cerebral artery occlusion (MCAO) model after a single intravenous (i.v.) injection. Altogether, well-defined cl-nanozymes are promising modalities for attenuation of oxidative stress after brain injury.

KW - Antioxidant enzymes

KW - Block ionomer complexes

KW - Blood-brain barrier

KW - Cross-linked nanozymes

KW - Stroke therapy

UR - http://www.scopus.com/inward/record.url?scp=84865811163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865811163&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2012.07.044

DO - 10.1016/j.jconrel.2012.07.044

M3 - Article

VL - 162

SP - 636

EP - 645

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -